<?xml version="1.0" encoding="UTF-8"?>
<ref id="B27-viruses-12-00838">
 <label>27.</label>
 <element-citation publication-type="web">
  <person-group person-group-type="author">
   <name>
    <surname>Cooper</surname>
    <given-names>D.A.</given-names>
   </name>
   <name>
    <surname>Gatell</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Rockstroh</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Katlama</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Yeni</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Isaacs</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Teppler</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Nguyen</surname>
    <given-names>B.-Y.</given-names>
   </name>
  </person-group>
  <article-title>Results of BENCHMRK- 1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus. CROI 25â€“28 Febuary 2007, Los Angeles. Abstract</article-title>
  <comment>Available online: 
   <ext-link ext-link-type="uri" xlink:href="http://www.natap.org/2007/CROI/croi_40.htm" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.natap.org/2007/CROI/croi_40.htm</ext-link>
  </comment>
  <date-in-citation content-type="access-date" iso-8601-date="2020-07-06">(accessed on 6 July 2020)</date-in-citation>
 </element-citation>
</ref>
